ArticleDiscovery medicine2010
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells.
Article in Discovery medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).Annals of oncology : official journal of the European Society for Medical Oncology · 2017Guideline
- Mapping the landscape: a bibliometric study of global chimeric antigen receptor T cell immunotherapy research.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- CAR T therapies in multiple myeloma: unleashing the future.Cancer gene therapy · 2024Review
- Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma.Pathogens & immunity · 2024Review
- Current updates on generations, approvals, and clinical trials of CAR T-cell therapy.Human vaccines & immunotherapeutics · 2022Article
- Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.Frontiers in immunology · 2022Review
- CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas.International journal of molecular sciences · 2020Review
- [Chimeric antigen receptors T cells for treatment of B-cell acute lymphoblastic leukemia previously infected with hepatitis B virus: two cases report and literatures review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Review
- Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.Current treatment options in oncology · 2020Review
- Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.International journal of molecular sciences · 2020Review
- The 100 Most Influential Studies in Chimeric Antigen Receptor T-Cell: A Bibliometric Analysis.Frontiers in medical technology · 2020Article
- CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.Leukemia · 2019Review
- Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.Antibodies (Basel, Switzerland) · 2019Review
- At the Intersection of Biomaterials and Gene Therapy: Progress in Non-viral Delivery of Nucleic Acids.Frontiers in bioengineering and biotechnology · 2019Review
- Universal CARs, universal T cells, and universal CAR T cells.Journal of hematology & oncology · 2018Review
- Frontiers and Opportunities: Highlights of the 2Antibody therapeutics · 2018Article
- Fludarabine and neurotoxicity in engineered T-cell therapy.Gene therapy · 2018Article
- [Anti-CD19 chimeric antigen receptors T cells for treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: three cases report and literatures review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018Article
- Current progress in innovative engineered antibodies.Protein & cell · 2018Review
- Clinical trials of CAR-T cells in China.Journal of hematology & oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chemotherapy-resistant B-cell hematologic malignancies may be cured with allogeneic hematopoietic stem cell transplantation (HSCT), demonstrating the potential susceptibility of these tumors to donor T-cell mediated immune responses. However, high rates of transplant-related morbidity and mortality limit this approach. For this reason, there is an urgent need for less-toxic forms of immune-based cellular therapy to treat these malignancies. Adoptive transfer of autologous T cells genetically modified to express chimeric antigen receptors (CARs) targeted to specific tumor-associated antigens represents an attractive means of overcoming the limitations of conventional HSCT. To this end, investigators have generated CARs targeted to various antigens expressed by B-cell malignancies, optimized the design of these CARs to enhance receptor mediated T cell signaling, and demonstrated significant anti-tumor efficacy of the resulting CAR modified T cells both in vitro and in vivo mouse tumor models. These encouraging preclinical data have justified the translation of this approach to the clinical setting with currently 12 open clinical trials and one completed clinical trial treating various B-cell malignancies utilizing CAR modified T cells targeted to either the CD19 or CD20 B-cell specific antigens.
Indexed as
Identifiers
20423671PMC4697441W1948401147What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.